2Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res, 2011, 17 : 1225-1233.
3Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma, 2010, 51 : 213-220.
4Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in on- cology. Clin Cancer Res, 2010, 16: 4084-4093.
5Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep, 2007, 5: 98-104.
6Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by nmhiple myeloma ceils. Blood, 2002, 100: 3002-3007.
7Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts snr- viva/in multiple myeloma: proposal for a novel prognostic index. Blood, 2003, 102: 1064-1069.
8Jakob C, Goerke A, Terpos E, et al. Serum levels of total-RANKL in multiple myeloma. Clin Lymphoma Myeloma, 2009, 9: 430- 435.
9Oyajobi BO, Franehin G, Williams PJ, et al. Dual effects of mac- rophage inflammatory protein-l alpha on osteolysis and tumor bur- den in the murine 5TGM1 model of myelmna bone disease. Blood, 2003, 102: 311-319.
10Lentzsch S, Gries M, Janz M, et al. Macrophage inflammatory protein 1-alpha (MIP-I alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) ceils. Blood, 2003, 101 : 3633-2646.
2Galibert P, Deramond H, Rosat P, et al. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty[J]. Neurochirurgie, 1987,33 (2) : 166-168.
3Bosnjakovi P, Risti S, Mrvi M, et al. Management of painful spinal lesions caused by multiple myeloma using pereutaneous acrylic cement inj ection[J]. Acta Chir Iugosl, 2009,56 (4) : 153- 158.
4Yang Z,Tan J,Xu Y,et al. Treatment of MM-associated spinal fracture with percutaneous vertebroplasty(PVP) and chemo- therapy[J]. Eur Spine J, 2012,21 (5) : 912-919.
5Dutoit JC,Vanderkerken MA, Verstraete KL. Value of whole body MRI and dynamic contrast enhanced MRI in the diagnosis, follow-up and evaluation of disease activity and extent in multiple myeloma[ J]. Eur J Radio1,2013,82 (9) : 1444-1452.
6Deanna J,Stessman H, Sagar S, et al. Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy [ J ]. J Cancer,2014, 5 (9) : 720-727.
7Nishino M, Jackman DM, Hatabu H, et al. New response evaluation criteria in solid tumors ( RECIST ) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy [ J ]. AJR Am J Roentgenol, 201 O, 195 ( 3 ) : W221-228.
8Pag6 MG, Katz J, Stinson J, et al. Validation of the numerical rating scale for pain intensity and unpleasantness in pediatric acute postoperative pain : Sensitivity to change over time [ J ]. J Pain,2012,13 (4) :359-369.
10Tan D, Kim K, Kim JS,et al. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM) : A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network[ J]. Leuk Res ,2013,37 (9) : 1070-1076.
